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Abstract
Gastrointestinal neoplasms in dogs represent a challenge for the veterinary clinician and surgeon as they are mostly 
malignant and when the owner notices the primary clinical changes the disease may already be in an advanced stage. 
Due to the high clinical and histopathological similarity between mesenchymal gastrointestinal neoplasms, it is often 
impossible to establish the definitive morphological diagnosis using light microscopy alone. In addition, there are only 
a few articles describing the anatomopathological and immunohistochemical characteristics, which make its complete 
characterization urgent and relevant in our context in order to assist the veterinary clinician, surgeon, and pathologist 
in establishing a precise diagnosis of these tumors.
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Resumo
As neoplasias gastrointestinais em cães representam casos desafiantes ao clínico e cirurgião, pois são em sua maioria 
malignas e, quando as primeiras alterações clínicas são notadas pelo proprietário do animal, a doença pode estar em 
estágio de desenvolvimento muito avançado. Devido à elevada similaridade clínica e histopatológica entre as neoplasias 
gastrointestinais mesenquimais, muitas vezes não é possível estabelecer o diagnóstico morfológico definitivo apenas 
com a microscopia de luz. Acrescenta-se que são poucos os artigos que descrevem as características anatomopatológicas 
e imuno-histoquímicas das neoplasias mesenquimais gastrointestinais que acometem os cães, o que torna premente 
a caracterização destas em nosso contexto, com o intuito de auxiliar clínico, cirurgião e patologista veterinário a 
estabelecer o diagnóstico destes tumores.
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The non-hematopoietic gastrointestinal mesenchymal 
neoplasms present a great challenge to the veterinarian, 
since they present incipient evolution, nonspecific clinical 
alterations, and high histomorphological similarity 
(GUILFORD; STROMBECK, 1996). These general 
characteristics make the early and definitive diagnosis 
difficult, because when the owner recognizes the first 
clinical manifestations, these types of neoplasm usually 
are in advanced development stage (WASHABAU, 2013; 
LEANDRO; SÁ, 2015). Early diagnosis may increase the 
therapeutic options and ultimately the patient’s survival 
and quality of life (LEIBMAN et al., 2003). Thus, the 
purpose of this review is to provide relevant and modern 
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information in order to assist the clinician, surgeon, and 
veterinary pathologist in setting the definitive diagnosis 
of non-hematopoietic gastrointestinal mesenchymal 
neoplasms in dogs.
Most gastrointestinal tract primary neoplasms are 
malignant and account for approximately 2% of all 
canine neoplasms; these diseases may be of epithelial, 
neuroendocrine, hematopoietic, and non-hematopoietic 
mesenchymal origin (BETTINI et al., 2003). The non-
hematopoietic mesenchymal gastrointestinal neoplasms 
comprise 16% of all neoplasms of the digestive system, 
mainly affecting the large intestine with the cecum being 
the most affected site (BETTINI et al., 2003; CERIEL et al., 
2007). The prevalence of colonic and rectal tumors in dogs 
is 2.8 to 4.1 for 10,000 dogs in the United States of America 
(LEIBMAN et al., 2003; RUSSEL et al., 2007). There are no 
studies with this type of information in Brazilian literature, 
but male dogs are the most affected and present a mean age 
of 9.8 years at the time of diagnosis (WASHABAU, 2013).
Breeds such as West White Highland Terriers, Chow 
Chow, Collie, American Staffordshire Terrier, German 
Shepherd, Maltese, and Bull Terrier are predisposed 
to develop gastrointestinal neoplasms (GUILFORD; 
STROMBECK, 1996; LEIBMAN et al., 2003; LEANDRO; 
SÁ, 2015). Approximately 40% of the dogs with non-
hematopoietic gastrointestinal mesenchymal neoplasms 
exhibit the average survival time of 12 months 
(CRAWSHAW et al., 1998). This parameter is influenced 
by anatomical lesion location, size of the neoformation, 
presence or absence of metastases, and compromised or 
free surgical margin. These criteria are fundamental for the 
veterinarian to take into consideration in order to estimate 
the prognosis of each case (BETTINI et al., 2003; CERIEL 
et al., 2007).
Macroscopically, such neoplasms are large, 
irregular nodular formations ranging from 2.5 to 30 
cm in diameter, mainly affecting the mucosa, muscular 
layer, and the anti-mesenteric border of the intestinal 
segments (LANGENBACK et al., 1998; FROST et al., 
2003; CERIEL et al., 2007; RUSSEL et al., 2007). The 
morphological characteristics are proliferation of fusiforms 
to polygonal and sometimes epithelioid cells, located in 
the gastrointestinal wall tract (MIETTINEN; LASOTA, 
2001; FLETCHER et al., 2002; HAYES et al., 2013). In 
this group are included gastrointestinal stromal tumor 
(GIST), leiomyomas (LM), leiomyosarcomas (LMS), 
peripheral nerve sheath tumors (PNST), osteosarcomas, 
and undifferentiated sarcomas (LANGENBACK et al., 
1998; BETTINI et al., 2003; FROST et al., 2003; CERIEL 
et al., 2007).
Studies using genetic and immunohistochemical 
markers have revolutionized the diagnosis of mesenchymal 
neoplasms in human and veterinary medicine, since it 
has become possible to classify the origin of neoplasias, 
allowing a better understanding of their biological behavior, 
epidemiology, and clinical presentation, sometimes 
allowing specific treatment (CERIEL et al., 2007; HAYES 
et al., 2013). In the recent past all cases of gastrointestinal 
mesenchymal neoplasia were considered sarcomas which 
carried poor prognoses, besides that all types were treated 
clinically and therapeutically in a similar manner (CERIEL 
et al., 2007; HAYES et al., 2013).
Main clinical presentation in dogs with 
gastrointestinal neoplasms
Clinical presentation in dogs with gastrointestinal 
tumors include slow progressive gastrointestinal 
manifestations that do not indicate the histomorphologic 
origin of the neoplasia, but may lead the clinician to the 
affected region of the gastrointestinal tract (GUILFORD; 
STROMBECK, 1996; LEIBMAN et al., 2003; RUSSEL et al., 
2007). Non-gastrointestinal clinical signs, such as anemia, 
ascites, polyuria / polydipsia, may also be associated with 
these tumors (COHEN; POST, 1999; CRAWSHAW et al., 
1998; LEIBMAN et al., 2003; LEANDRO; SÁ, 2016).
The involvement of the proximal segments of the 
gastrointestinal tract, such as the stomach and duodenum, 
are related to manifestations of emesis, melena, anorexia and 
abdominal distension (LEIBMAN et al., 2003). Hematemesis 
occurs in more than 50% of dogs with gastric neoplasms 
and is due to mucosal ulcers, hemorrhages, stenosis, and 
obstructions located in the gastric body and / or pylorus 
(LEANDRO; SÁ, 2015). Diarrhea is a common clinical 
change in neoplasms located in jejunum and ileum, whereas 
dyskinesia and hematochezia are often associated with 
neoplastic involvement in cecum and colon (LEANDRO; SÁ, 
2015). Tenesmus and rectal prolapse are manifestations that 
are related to neoplasms located in the rectum (LEIBMAN 
et al., 2003; WASHABAU, 2013). The neoplasias located in 
the cecum present a greater chance of developing intestinal 
rupture and septic peritonitis, compared to neoplasias in 
the small intestine (CERIEL et al., 2007).
Nonspecific clinical signs of the gastrointestinal 
tract also occur and need to be considered, such as: 
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hyporexia, weight loss, abdominal pain, and peritonitis 
(GUILFORD; STROMBECK, 1996; LEANDRO; SÁ, 2015). 
Paraneoplastic syndromes, anemia, clinical alterations 
due to intestinal obstruction, and malabsorption may 
be associated with gastrointestinal neoplasia (LAROCK; 
GINN, 1997; COHEN, POST, 1999; CRAWSHAW et al., 
1998; LEANDRO; SÁ, 2016). The clinician and surgeon 
need to consider among the differential diagnoses the 
ulceroproliferative processes of inflammatory bowel 
disease, gastrointestinal infectious processes and other 
gastrointestinal neoplasms, such as lymphoma and 
adenocarcinoma (TURK et al., 1981; HEAD et al., 2002).
In some patients it is possible that abdominal palpation 
indicates the presence of increased intra-abdominal 
volumes and radiographic and / or ultrasonographic 
evaluation guides the clinician for the possibility of a 
neoplastic gastrointestinal process (HANAZONO et al., 
2012; CONSTANT; POLF 2015).
Gastrointestinal Stromal Tumor (GIST)
GIST is the most common mesenchymal neoplasm 
of the gastrointestinal tract, accounting for 50 to 60% of 
the cases in dogs (CERIEL et al., 2007). There is also a 
description of GIST in horses, non-human primates, and 
humans (HAYES et al., 2013; IRIE et al., 2015; LEANDRO, 
SÁ, 2015).
GISTs occur, in 48% of the cases, mainly located in the 
large intestine (LI), followed by 29% in the small intestine 
(SI), 19% in the stomach, and 5% in the mesentery (FROST 
et al., 2003). Cecum is the main site of involvement in 
dogs and the mean age at diagnosis is 10.7 years old. In 
this location GIST is associated with greater aggressive 
behavior and risk of intestinal perforation, peritonitis, and 
septicemia (CERIEL et al., 2007; IRIE et al., 2015).
From the morphological point of view, four 
morphological patterns of GIST are described in dogs 
and in men, although the patterns can be mixed in the 
same tumor: storiform, myxoid, fascicular, and epithelioid 
(HEAD et al., 2002; HAYES et al., 2013; LEANDRO; SÁ, 
2016). It is considered that the fascicular and estoriform 
patterns are the most frequent in humans, followed by the 
epithelioid and mixed patterns (MIETTINEN; LASOTA, 
2001; ZAO; YUE, 2012). In dogs the fascicular pattern 
is the most common and in some cases a mixed pattern 
formed by the fusiform and epithelioid may be found 
(CERIEL et al., 2007; HAYES et al., 2013).
The fusiform GIST is composed of short interlaced 
fascicles of cells with elongate nuclei, eosinophilic 
and fibrillar cytoplasm, as shown in figures 1B. In 
some circumstances it may present patterns of neural 
differentiation, such as nuclei palisade stratification. 
The epithelioid pattern consists of nests or cords of cells 
with ovoid or rounded nuclei, presenting eosinophilic 
cytoplasm and being frequently present perinuclear 
cytoplasmic vacuoles. The stroma can be hyalinized 
or myxoid. When present, focuses of necrosis and 
hemorrhage may be associated with malignancy, a 
variable number of macrophages containing cytoplasmic 
hemosiderin granules distributed at the periphery of 
the neoplasm or between neoplastic cells (HEAD et al., 
2002; CERIEL et al., 2007; RUSSEL et al., 2007; HAYES 
et al., 2013).
A B
Figure 1 –  Example of histomorphological similarity between intestinal sarcomas in dogs. A. leiomyosarcoma in the intestine; B. 
Gastrointestinal stromal tumor (GIST) in intestine, hematoxylin and eosin, 200x
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GISTs mainly compromise the submucosal and muscular 
layers, and may in some cases compromise all layers of the 
gastrointestinal tract (HAYES et al., 2013; LEANDRO; 
SÁ, 2016). Mitotic index is quite variable and allied to the 
macroscopic size of the tumor represents the main way of 
estimating the malignancy potential and aggressiveness of 
these neoplasms, both in humans and animals (HANAZONO 
et al., 2012; HAYES et al., 2013; LEANDRO, SÁ, 2016).
Some characteristics used in human medicine to 
assess the metastatic risk of GIST are presented in table 1, 
which was adapted from the information collected from 
the following authors (MIETTINEN; LASOTA, 2001; 
FLETCHER et al., 2002; ZAO; YUE, 2012). Based on 
this information, dogs with tumors larger than 5 cm 
with ultrasonographic features characterized by irregular 
surface and heterogeneous appearance with hypoechoic 
areas at the center of the tumor have a reserved prognosis 
and a greater risk of distant metastasis, whereas lesions 
smaller than 5 cm show a better evolution, with better 
survival rates (HAZAZONO et al., 2012).
Table 1 –  Risks of aggressive behavior of GIST related to size and counting of mitotic figures in human neoplasms – São Paulo – 
2017 (adapted from FLETCHER et al., 2002)
Risk of aggressive behavior Size Count of mitosis figures
Very low risk < 2cm < 5/50 fields of 400 x
Low risk 2-5 cm < 5/50 fields of 400 x
Intermediate risk < 5 cm 6-10/50 fields of 400 x
< 5 cm < 5/50 fields of 400 x
High risk > 10 cm Any mitosis rate
Any size > 10/50 fields of 400 x
There is evidence of GIST metastasis due to 
hematogenous dissemination in 30% of cases, with 
the liver, intestinal serous surface or abdominal cavity 
being the most frequent sites. However, bone and lung 
metastases are rare (FROST et al., 2003; CERIEL et al., 
2007; HAYES et al., 2013). The mean survival rate of dogs 
with GIST submitted to the surgical procedure of mass 
removal, without adjuvant chemotherapeutic treatment 
is 11.6 months from the definitive diagnosis (CERIEL et 
al., 2007).
GIST has peculiar immunohistochemical and 
genetic characteristics that differentiate it from other 
gastrointestinal tract neoplasms (BETTINI et al., 2003). 
Immunohistochemical studies revealed that GIST can be 
classified according to differentiation in smooth muscle 
(myogenic), neural tissue (neurogenic), combination of 
both (mixed) or undifferentiated (anaplastic), justifying 
their difficult morphological diagnosis by traditional 
methods of microscopy (CERIEL et al., 2007; HAYES et 
al., 2013).
Regarding immunostaining, GISTs are 100% positive 
for vimentin, and negative for epithelial cell markers such 
as cytokeratin AE1/AE3, and hematopoietic markers 
such as CD3 (T lymphocytes), CD20, and CD79 (B 
lymphocytes), as well as for the glial fibrillary acidic protein 
(GFAP) (MIETTINEN; LASOTA, 2001; CERIEL et al., 
2007; HAYES et al., 2013)
The immunohistochemical marker CD117 (c-KIT), 
which is the marker of choice for differentiating GIST, is 
present in up to 60%-70% of malignant GISTs in dogs, and 
shows diffuse and strong cytoplasmic immunoreactivity 
as represented by the figure 2A, being absent in primary 
neoplasms of muscular and nerve sheath origin (FROST 
et al., 2003; CERIEL et al., 2007; RUSSEL et al., 2007; 
HAYES et al., 2013). Thus, CD117 immunostaining is 
important for the definitive diagnosis and prognosis of 
this neoplasm.
In cases of malignant mesenchymal neoplasms of 
fusiform cells and negative c-KIT a further definitive 
diagnostic strategy option is the use of the DOG 1 antibody, 
which presents specificity and sensitivity in cases of GISTs 
and, thus, may be included in the immunohistochemical 
panel (LIEGL et al., 2009; DAILEY et al., 2015).
The immunoexpression of smooth muscle actin (SMA) 
and / or desmin are observed in normal and neoplastic 
smooth muscle cells, benign or malignant, and in some 
fibroblasts. A significant subset of GIST with myogenic 
differentiation is positive in 33% - 40% for SMA and 80% 
- 82% for desmin (LAROCK; GINN, 1997; CERIEL et al., 
2007; LIEGL et al., 2009; HAYES et al., 2013).
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The S100 protein is a typical marker of lesions originating 
from the myenteric nervous plexus, which is present mostly 
in neoplasms of neural origin, and absent in muscle-
derived neoformations (CERIEL et al., 2007; HANAZONO 
et al, 2012). In 68% - 73% of neurogenic GISTs positive 
immunoreactivity for S100 protein is observed (LAROCK; 
GINN, 1997; CERIEL et al., 2007; HAYES et al., 2013). CD34 
antibody is a cell surface glycoprotein, and it was originally 
described in precursor cells of myeloid and lymphoid tissue in 
the bone marrow. In addition, 60% - 70% of all GISTs located 
in the esophagus and rectum are CD34-positive in humans 
(GILLESPIE et al., 2011). There is no significant difference 
in CD34 expression between benign and malignant GISTs 
(GILLESPIE et al., 2011). Table 2 presents the summary of the 
recommended immunohistochemical panel for the diagnosis 
and differentiation of GIST (LEANDRO; SÁ, 2016).
A B
Figure 2 –  Histomorphological aspect of gastrointestinal stromal tumor (GIST) and intestinal 
osteosarcoma in dogs. A. GIST, CD117 (c-KIT) positive immune reaction, Streptavidin-
biotin-peroxidation by Harris haematoxylin. IHQ, 200 x, B. Histomorphological aspect of 
intestinal osteosarcoma in dogs. Hematoxylin and eosin, 200 x
Table 2 –  Antibody panel recommended for the diagnosis and characterization of GIST – São Paulo – 2017 (adapted from 
LEANDRO; SÁ, 2016)
   Antibodies     
Differentiation Vimentin CD117 DOG-1 S100* SMA# Desmin CK 20¥
GIST neurogenic + + + + - - -
GIST miogenic + + + - + + -
GIST anaplastic + + + - - - -
GIST mixed + + + + + + -
* protein S100; # SMA (smooth muscle actin), ¥ CK 20 (cytokeratin 20)
The main histopathological differential diagnoses 
for GIST are leiomyoma, leiomyosarcoma, poorly 
differentiated sarcoma, and peripheral nerve sheath tumor 
(HAYES et al., 2013). The immunohistochemical reaction 
is very useful in the differential diagnosis, since these 
neoplasms do not express c-KIT and DOG 1 (LAROCK; 
GINN, 1997; COHEN et al., 2003). It should be noted that 
the expression of c-KIT is not restricted to GIST, since 
positive immuno-tagging is also observed in melanoma, 
germ cell tumors, astrocytomas, seminomas, and 
angiosarcomas (MIETTINEN; LASOTA, 2001). It stands 
out that these neoplasias exhibit specific morphology 
and immunoreactivity for other antibodies that aid the 
definitive morphological diagnosis.
Smooth muscle neoplasms
Smooth muscle neoplasms involve animals with 
a mean age of 11.8 years for neoplasms located in the 
cecum and 10.3 years for neoformations that affect the 
stomach, duodenum, and jejunum (COHEN et al., 2003; 
FARESE et al., 2008; HAYES et al., 2013). Prevalence 
ranges from 12 - 120 cases / 10,000 dogs; in which the LM 
and the LMS consist of 10%-30% of all the gastrointestinal 
mesenchymal tumors that affect dogs (COHEN et al., 
2003; LEIBMAN et al., 2003; PARK et al., 2007; FARESE 
et al., 2008).
Smooth muscle neoplasms are characterized by 
proliferation of elongated to fusiforms cells, arranged in 
long interlocking bundles. The cytoplasm of the neoplastic 
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cells is eosinophilic with imprecise boundaries, the elongate 
nucleus has straight edges and features that resemble cigars, 
and the nucleolus is generally not clear. The high ratio of 
nucleus: cytoplasm, foci of necrosis, and haemorrhage may 
be present in the malignant form, as shown in figure 1A. The 
stromal can be dense and collagenous, well-vascularized or 
myxomatous, with cavity spaces and areas with few cells 
(MIETTINEN et al., 2001; HEAD, et al., 2002; FROST et 
al., 2003; PARK et al., 2007; FARESE et al., 2008).
Sometimes the differentiation between benign and 
malignant is challenging. Morphological criteria used for 
differentiation include count of mitosis figures, areas of 
necrosis, haemorrhage, and presence of angiolymphatic 
invasion in malignant cases. Thus, counts above 10 mitoses 
/ field 400 x are indicative of malignancy (LAROCK; 
GINN, 1997; HEAD, et al., 2002; COHEN et al., 2003; 
FARESE et al., 2008).
Macroscopically, LMS and LM are characterized by 
being large single formations, polypoid, larger than 5 cm, 
with imprecise boundaries due to involvement of adjacent 
tissues, compromising the muscular and mucosal layers, 
may be located in the esophagus, jejunum, cecum, and 
colorectal portion (CERIEL et al., 2007; RUSSEL et al., 
2007; CONSTANT et al., 2015; HOBBS et al., 2015). 
The occurrence of intestinal perforation, peritonitis, and 
subsequent sepsis can occur in 50% of intestinal LMS in 
dogs (COHEN et al., 2003).
The immunohistochemical classification of LM / LMS 
is based on positive immunoexpression for vimentin, 
which is a specific marker for mesenchymal neoplasms, 
and immunomarker for smooth muscle actin (SMA) 
and desmin (RUSSEL et al., 2007). In well differentiated 
neoplasms it is possible to find strong reactivity for SMA 
and desmin, but weak for vimentin. In cases with poorly 
differentiated neoplasms the intensity of reactivity for 
vimentin is strong and for SMA is weak. This finding 
may suggest malignant neoplasm behavior (HAYES et al., 
2013). It is important to note that in the smooth muscle 
neoplasias, the expression of c-Kit, DOG1, S100 protein, 
cytokeratin AE1/AE3, CD3, CD20, and CD79 are not 
observed (MIETTINEN et al., 2001; CERIEL et al., 2007; 
RUSSEL et al., 2007).
In humans, prognostic indicators for LMS include 
the immunohistochemical detection of the MDR-
1 gene, P-glycoprotein (P-gp), and multiple drug 
resistance protein-1 (MRP-1) (PLAAT et al., 2000). The 
expression of these proteins in humans is associated 
with multiresistance to several chemotherapeutic drugs, 
such as the anthracyclines, doxorubicin and epirubicin 
(PLAAT et al., 2000). Expression of MRP-1 proteins is 
less pronounced in LMS when compared to GIST cases 
in humans, suggesting that LMS may be more sensitive to 
conventional chemotherapeutic agents than GIST (PLAAT 
et al., 2000). In dogs the application of these prognosis 
immunomarkers is unknown.
At the time of diagnosis 16% to 37.5% of dogs with 
intestinal LMS have intra-abdominal metastases and the 
most affected sites are the liver, peritoneum, mesentery, or 
mesenteric lymph nodes (COHEN et al., 2003; RUSSEL et 
al., 2007; CONSTANT et al., 2015).
Several studies point to hypoglycemia as the main 
paraneoplastic syndrome of animals with abdominal LMS. 
Hypoglycemia results from the production of insulin-like 
hormone by neoplasia (BAGLEY et al., 1996). In addition, 
the high glucose demand due to high tumor metabolism 
combined with the decrease in hepatic gluconeogenesis 
secondary to hepatic metastasis damages are also factors 
that contribute to hypoglycemia. Polyuria and polydipsia 
are present in 36% of dogs with intestinal LMS, which 
develop nephrogenic diabetes insipidus (COHEN; POLF, 
1999). Animals presenting with LM in cecum present a 
shorter survival time (mean of 7.5 months) when compared 
to the survival rate of neoplasms located in the stomach, 
jejunum, and duodenum, for which the survival period 
is 1.1 years (COHEN et al., 2003; FROST et al., 2003; 
RUSSEL et al., 2007; CONSTANT et al., 2015; HOBBS et 
al., 2015). Animals that have an early clinical diagnosis 
and are submitted to medical and surgical treatment tend 
to not relapse in 40% to 60% of cases and present higher 
survival rate (CRAWSHAW et al., 1998).
Comparison between the parameters adopted to 
measure the postoperative survival of human patients 
includes the mitotic index and the size of the neoformation 
(MIETTINEN et al., 2001). Formations larger than 5 cm 
may show malignant behavior and metastasis frequently, 
even when the tumor exhibits reduced numbers of mitoses 
per field (MIETTINEN et al., 2001).
Neurogenic Neoplasms
Gastrointestinal neurogenic sarcomas are uncommon 
and have been reported in dogs and horses (KIRCHHOF 
et al., 1996; SCHÖNIGER; SUMMERS, 2009). These 
neoplasias usually involve the cranial nerves, spinal nerve 
roots or subcutaneous tissue more frequently than the 
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segments of the gastrointestinal tract (CAMPBELL et 
al., 2003). Neurogenic sarcomas are usually classified as 
neurofibrosarcoma and schwannoma (KIRCHHOF et al., 
1996; HEAD et al., 2002). The World Health Organization 
has grouped neoplasms that originate from Schwann 
cells, fibroblasts or perineural cells, such as nerve sheath 
neoplasm that may be benign or malignant (HEAD et al., 
2002; SCHÖNIGER; SUMMERS, 2009).
Animals with neoplasias of neurogenic gastrointestinal 
origin present an average age of 9 years old at the time 
of diagnoses. The small intestine is the main site of 
development and there is involvement of the submucosa 
and muscle layer (SCHÖNIGER; SUMMERS, 2009; 
HAYES et al., 2013).
Macroscopically this neoplasm is circumscribed, 
firm, and has smooth surface (HAYES et al., 2013). 
Histomorphologically they may present two distinct 
patterns named Antoni A and Antoni B. The first is the 
most common and is characterized by the proliferation 
of fusiform cells arranged in long or short parallel beams 
distributed in multiple directions (KIRCHHOF et al., 
1996; HEAD et al., 2002; SCHÖNIGER; SUMMERS, 
2009; HAYES et al., 2013). The cells have elongated, 
oval or fusiforms nuclei. The cytoplasm is eosinophilic 
and has poorly defined limits. In this pattern, the 
arrangement of nuclei is in parallel clusters (palisade) 
arranged concentrically around acellular areas composed 
of amorphous collagen, known as Verocay corpuscles 
(SCH6ONIGER; SUMMERS, 2009; HAYES et al., 2013). 
The nuclei are pleomorphic and hyperchromatic with a 
distinct basophilic nucleolus. The mitotic index is low. 
The morphological pattern Antoni B is less common and 
presents areas of low cellular density, formed by fusiform 
or rounded cells, freely organized in a loose myxomatous 
stroma (HEAD et al., 2002; SCHÖNIGER, SUMMERS, 
2009; HAYES et al., 2013).
The immunohistochemical markers applied in the 
characterization of these neoplasms are vimentin, protein 
S-100, PGP 9.5, and glial fibrillating acidic protein (GFAP) 
presenting cytoplasmic reactivity (CAMPBELL et al., 2003; 
HAYES et al., 2013). These immunomarkers are expressed 
in a wide variety of tissues and have been recognized 
as markers to identify a neurogenic differentiation of 
mesenchymal neoplasms (HAYES et al., 2013). Neurogenic 
sarcomas that are vimentin and S-100 positive, and PGP 
9.5 negative are associated with the morphological pattern 
Antoni B (CAMPBELL et al., 2003). Neurogenic sarcomas 
are negative for smooth muscle markers, SMA and desmin, 
c-Kit, epithelial marker, cytokeratin AE1/AE3, and CD3, 
CD20, and CD79 (SCHÖNIGER, SUMMERS, 2009; 
HAYES et al., 2013).
In general, reports in human medicine indicate that 
peripheral nerve sheath tumors that compromise the 
digestive tract have a benign behavior and do not present 
distant metastases, however, as the surgical treatment 
is delayed, they show a tendency to affect local mass, 
compromising adjacent tissues (LU et al., 2015). The 
behavior and survival of dogs presenting gastrointestinal 
peripheral nerve sheath neoplasms are unknown due to 
the lack of reports highlighting this information.
Intestinal osteosarcoma
Extra-skeletal osteosarcomas are malignant 
mesenchymal neoplasms producing osteoid matrix that 
occur in soft tissues and organs, and do not present 
concomitant bone or periosteal involvement. There is no 
definitive underlying cause, but some authors point out the 
participation of undifferentiated pluripotential cells in the 
etiopathogenesis of these neoplasms (LANGENBACK et 
al., 1998; DUFFY et al., 2017).
The extrahepatic osteosarcoma may present osteoblastic, 
chondroblastic, fibroblastic, osteochondroblastic, and 
histiocytic differentiation (LANGENBACK et al., 1998; 
MACKENZIE, et al., 2012). Osteoblastic osteosarcoma 
is the most common histological type, being reported 
in 63.6% of cases of extrahepatic canine osteosarcoma, 
mainly affecting the mammary gland, spleen, testicles, eyes, 
vagina, kidneys, and liver (LANGENBACK et al., 1998; 
URBIZTONDO et al., 2010; DUFFY et al., 2017).
The intestinal extraskeletal osteosarcomas are 
uncommon and mainly affect all the intestinal layers of 
the jejunum (PARDO et al., 1990; MACKENZIE, et al., 
2012). Macroscopically, these neoplasms are large tumors, 
whose measurements vary from 2.5 to 30 cm in diameter 
with a mean of 12.7 cm, which present irregular surfaces 
that extend from the intestinal muscle layers to the mucosa 
(LANGENBACK et al., 1998; URBIZTONDO et al., 2010; 
DUFFY et al., 2017). These tumors are characterized by 
polygonal mesenchymal cells with pleomorphic fusiform, 
with large vesicular nucleus and eosinophilic cytoplasm. 
There is production of osteoid matrix, as shown in figure 
2B, which sometimes mineralizes forming bone trabeculae. 
This peculiarity is not always present in these tumors and 
calcification is not reactive or metaplastic. The number 
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of mitosis figures per field is variable and can be high 
(PARDO et al., 1990; LANGENBACK et al., 1998; DUFFY 
et al., 2017).
Immunohistochemical characterization is limited in the 
case of osteosarcoma due to the absence of specific markers, 
but these tumors are positive for vimentin. The anti-
osteonectin antibody is poorly sensitive and can react with 
various cell types including active osteoblasts, immature 
osteocytes, fibroblasts, and epithelial cells (PARHAM, 2015; 
WEHRLE-MARTINEZ et al., 2016). Anti-osteopontin 
antibody also has low sensitivity, and although studies 
have shown expression in osteosarcomas, this antibody 
also presents immunoreaction in the epithelium of the 
gastrointestinal tract, gallbladder, pancreas, urinary, and 
reproductive tracts, salivary and sweat glands, as well as 
vascular endothelial cells, macrophages, and myoepithelial 
cells, and there is no immunostaining. in hematopoietic 
neoplasms (PARHAM, 2015; WEHRLE-MARTINEZ et al., 
2016). The anti-osteocalcin antibody reacts with osteocytes 
of adult bone and presents positive immunostaining 
in 66.6% of cases of low-grade, well-differentiated 
osteosarcomas; therefore it is more specific when 
compared to osteonectin and osteopontin (WEHRLE-
MARTINEZ et al., 2016). In contrast, the immunostaining 
of osteocalcin is much lower in high-grade undifferentiated 
osteosarcomas, so its sensitivity is lower depending on the 
degree of differentiation of the neoplasia (PARHAM, 2015; 
WEHRLE-MARTINEZ et al., 2016).
On the other hand, the immunohistochemical panel 
is useful to determine the morphological origin and to 
differentiate the osteosarcomas from other mesenchymal, 
epithelial, and hematopoietic neoplasias that may present 
foci of bone matrix. Intestinal carcinomas are the most 
common gastrointestinal neoplasms in dogs, they are 
AE1/AE3 cytokeratin positive, negative vimentin, and 
may present areas of metaplastic production of the osteoid 
matrix secondary to the production of osteoinductive 
cytokines such as the β-transglobulin growth factor, 
fibroblasts growth factor, and insulin-like factors 1 and 2 
(TURK et al., 1981).
Intra-abdominal osteosarcomas present an aggressive 
behavior and worse prognosis associated with a high 
mortality rate when located in the gastrointestinal tract 
and liver (LANGENBACK et al., 1998; URBIZTONDO et 
al., 2010; MACKENZIE, et al., 2012; DUFFY et al., 2017).
Final considerations
Table 3 summarizes the main references that address 
the anatomopathological characteristics of gastrointestinal 
neoplasias affecting dogs according to segment of 
the gastrointestinal tract, intestinal wall location, 
immunomarkers and survival after diagnosis.
Table 3 –  Summary of the characteristics of the non-hematopoietic mesenchymal gastrointestinal neoplasms that affect dogs, 
second segment affected, involvement of the layers, immunomarkers, and survival after diagnosis in months – São Paulo 
– 2017
Parameters1\ Tumor2 GIST LMS/LM PNST Osteosarcoma
Segment LI E/ LI SI LI
Layers of the organ submucosa and muscular muscular and mucosa submucosa and muscular all layers
Vimentin + + + +
c-KIT(CD117) + - - -
DOG1 + - - -
Smooth muscle actin +/- + - -
Desmin +/- + - -
S 100 +/- - + -
PGF 9.5 - - + -
CD34 +/- - - -
CD3 - - - -
CD79α - - - -
CD20 - - - -
Cytokeratin AE1/AE3 - - - -
Survival 11,6 months 7,5-12 months No reports 1-4 months
References HAYES et al., 2013 RUSSEL et al., 2007 SCHONIGER; SUMMERS, 2009 DUFFY et al., 2015
2 GIST (gastrointestinal stromal tumor); LMS (leiomyosarcoma); LM (leiomyoma); PNST (peripheral nerve sheath tumor); E (esophagus) SI (small intestine); 
LI (large intestine)
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